Insilico Medicine and Eli Lilly announced a drug discovery collaboration on March 29, 2026, worth up to $2.75 billion12.
Insilico is eligible to receive $115 million upfront, with the remainder tied to development, regulatory, and commercial milestones, plus tiered royalties on future sales13.
Lilly receives an exclusive worldwide license for development, manufacturing, and commercialization of novel oral therapeutics in preclinical development across multiple therapeutic areas13.
The collaboration combines Insilico's Pharma.AI platforms with Lilly's clinical development expertise and disease-area knowledge for joint R&D programs13.
This partnership builds on previous collaborations between the companies, including an AI software licensing agreement from 2023 and a $100 million partnership from November 20252.
Insilico was founded in 2014 and completed a Hong Kong IPO in December 2025, raising $293 million2.
Insilico CEO Alex Zhavoronkov stated the partnership aims to deliver transformative therapies for diseases with high unmet need using AI to identify multi-purpose targets driving multiple diseases13.
Sources:
1. https://www.prnewswire.com/news-releases/insilico-medicine-announces-global-rd-collaboration-with-lilly-302727884.html
2. https://www.fiercebiotech.com/biotech/lilly-signs-275b-partnership-insilicos-ai-engine-pursuit-oral-therapeutics
3. https://insilico.com/news/uiy12zcjg1-insilico-medicine-announces-global-rampd